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Introduction 
     Since the late 1990s, industry-sponsored ghostwriting 
for the medical literature has been exposed in a number of 
articles, plaintiffs’ lawsuits and government investigations.  
Ghostwritten articles have been the main vehicle by which 
the pharmaceutical and medical device industries engage in 
the deliberate misrepresentation of efficacy and safety for 
product promotion and legal defense.1,2 
     In this regard, Sally K. Laden was one of the most 
prolific ghostwriters of the now-defunct medical 
communication company, Scientific Therapeutics 
Information (STI). A recently-posted document describes a 
marketing and publication plan by SmithKline Beecham, 
now GlaxoSmithKline (GSK) that commissioned STI to 
produce a manuscript for paroxetine treatment of panic 
disorder. In her correspondence with GSK managers, Laden 
wrote: “There are some data that no amount of spin will 
fix….”3 On the other hand, substantial data appeared in 
numerous articles ghostwritten by Sally Laden such as the 
paroxetine 329 adolescent depression trial, the paroxetine 
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352 bipolar depression trial and a special issue of  
Psychopharmacology Bulletin “Advancing the Treatment of 
Mood and Anxiety Disorders: The First 10 Years’ Experience 
with Paroxetine.”1,4-5 If Laden is acknowledged at all for 
having produced these manuscripts, she is mentioned only 
in the fine print, as in the case of study 329, for “editorial 
assistance.”6  These and other ghostwritten publications for 
GSK are listed among over 100 projects that GSK 
commissioned from STI in a document entitled, “Paxil-
Funded Publications 1998 to Current,” subpoenaed in 2008 
in the case of Burdick vs. GSK. In addition to ghostwriting 
articles and letters to the editor, STI ghostwriters also 
prepared continuing medical education programs, 
conference posters, speaker training materials, and slide 
kits. For example, project #1305, Nemeroff study #352, 
describes the project as follows: “Write up of a clinical study. 
STI provided editorial assistance to primary author: 
writing/editing, coordinating materials needed for journal 
submission.”7 Another item on this document is project 
#1112, “Handbook: Psychopharmacology, […] developed for 
clinical practitioners; overall editor C. Nemeroff,” which was 
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published as a textbook entitled Recognition and Treatment 
of Psychiatric Disorders: A Psychopharmacology Handbook 
for Primary Care under the authorship of Charles B. 
Nemeroff and Alan F. Schatzberg. It is hotly disputed as to 
whether this textbook was ghostwritten by STI.8 
     “Editorial assistance” was the euphemistic term STI 
used to describe ghostwriting. If, however, it were merely a 
matter of editorial assistance in the technical write up of 
clinical trial results, there would be no issue with what has 
become common practice. The problem, as we will 
demonstrate below, is concealing corporate input that 
misrepresents the data for marketing purposes.   
     As a result of newly-publicized documents that provide 
significant evidence of the misreporting of clinical trial 
results, this case study is a follow-up to our previous article, 
“The paroxetine 352 bipolar trial: A study in medical 
ghostwriting,” published in the International Journal of Risk 
and Safety in Medicine.5 In that article we critically 
evaluated the paroxetine 352 bipolar trial in order to 
demonstrate how the published report conflated primary 
and secondary outcome analyses, turning negative results 
into positive results―with conclusions that could adversely 
affect patient health. In the current deconstruction article, 
we examined forty-two publicly-available documents 
produced by Scientific Therapeutics Information, Inc. from 
paroxetine litigation. Forty of the documents were 
produced as part of In Re: Paxil, C.P. Ct. PA (On-Drug) and 
concern the production of the report of paroxetine study 
352. The remaining two documents were related to the 
publication plans for paroxetine and another clinical trial, 
paroxetine study 222 for panic disorder. The documents are 
posted on the Drug Industry Document Archive (DIDA) web 
site at the University of California San Francisco. 
 
The Paroxetine 352 Study and its Findings 
     Study 352, entitled “Double-Blind, Placebo-Controlled 
Comparison of Imipramine and Paroxetine in the Treatment 
of Bipolar Depression,” was published in the American 
Journal of Psychiatry in June 2001 under the byline of 
Nemeroff et al. (2001).9 It was designed as an 18-site, 10-
week, randomized, double-blind, placebo-controlled 
comparison of paroxetine versus imipramine in subjects 
with bipolar type I major depression unresponsive to lithium 
carbonate at therapeutic plasma lithium levels. It had a 
projected study duration of 2 years. Its protocol-designated 
objective was to compare the efficacy and safety of 
paroxetine and imipramine to placebo in the treatment of 
bipolar depression in subjects stabilized on lithium therapy. 
     The primary efficacy measures were the change from 
baseline Hamilton Rating Scale for Depression (HRSD) total 
score, and the change from baseline in the Clinical Global 
Impression Severity (CGI/S) score for paroxetine versus 
placebo and for imipramine versus placebo.9-11 The 
comparison of primary interest was paroxetine versus 
placebo irrespective of baseline lithium level stratification. 
Protocol-stipulated secondary outcomes included the 
proportion of subjects with a final HRSD score ≤ 7 or a final 
CGI/S score ≤ 2 as well as the proportion of subjects with 
adverse events, premature treatment discontinuation and 
manic or hypomanic symptoms as measured by the DSM-III-
R Mania/Hypomania Assessment and the Young Mania 
Rating Scale (YMRS).12  Analyses were to be performed on 
the entire subject population and on subjects who 
experienced a manic or hypomanic episode (versus those 
who did not). The YMRS measure was to be used to assess 
severity of manic and hypomanic symptoms across 
treatment groups, and the relationship between change in 
YMRS scores and HRSD scores was to be examined.   
   The study population consisted of outpatient subjects ≥ 
18 years old with a history of ≥ one prior manic or depressive 
episode within the preceding 5 years. The original protocol 
called for a sample size of 62 subjects per treatment 
condition (i.e., totaling 186 subjects). However, due to poor 
subject enrollment, only 117 subjects were recruited into 
the study, resulting in a final sample size distribution of 
paroxetine (n=35), imipramine (n=39), and placebo (n=43). 
As a result, the paroxetine 352 study was a non-informative 
trial with insufficient statistical power to show anything 
other than inconclusive results. There was no evidence of 
paroxetine or imipramine efficacy versus placebo in bipolar 
major depression, and the presentation of safety data were 
insufficient to draw any clinically meaningful conclusions. 
Despite the protocol stipulations, Nemeroff et al. failed to 
mention that the YMRS rating was employed as an outcome 
measure in the 352 study and most other manic and 
hypomanic safety ratings obtained with the YMRS measure 
were omitted from the published article. As a result, the 
published article inaccurately reported that there was no 
evidence of any paroxetine-induced manic and/or 
hypomanic symptoms in bipolar major depressive disorder 
while the suppression of safety data from the YMRS 
outcome measure hid the presence of possible paroxetine-
induced harm. 
 
Complaint of Research Misconduct in the 352 Study  
     In July 2011, a Complaint of Scientific Misconduct was 
filed with the Office of Research Integrity (ORI) of the 
Department of Health and Human Services against Dwight 
L. Evans, Laszlo Gyulai, Charles B. Nemeroff, Gary S. Sachs, 
Charles L. Bowden et al.13 As part of the formal adjudication 
process of the ORI misconduct case, the University of 
Pennsylvania organized a formal ORI Inquiry Committee 
comprised of three professors from the School of Medicine 
to investigate the allegations of misconduct.  
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     According to the complaint, the paroxetine 352 article 
was ghostwritten by employees of GSK and STI. It was 
published by the American Journal of Psychiatry in June 
2001 under the author byline of Nemeroff et al. without 
acknowledging the role of GSK or the STI ghostwriters. The 
complaint alleged: 14 
(1) “that Dr. Evans and Dr. Gyulai allowed their names to 
be appended to a manuscript drafted by a medical 
communications company and, thereby, Dr. Evans 
and Dr. Gyulai were not legitimate authors of the 
manuscript” (p.3);  
(2) “that the manuscript was ‘ghostwritten’ by STI and 
that the authors of the published manuscript failed 
to appropriately acknowledge STI's contribution” 
(p.3); 
(3) “the preliminary drafts of the study 352 article were 
conceptualized and drafted by STI and not by any of 
the named authors” (p.5); 
(4) “Dr. Evans' contribution to the preparation of the 
manuscript was limited to his commenting on, and 
approving, STI and GSK ghostwritten drafts of a 
manuscript on which he was designated as second 
author, and of which he had no direct knowledge of 
the accuracy of the data analyses, data 
interpretation (i.e., the inclusion or exclusion of 
particular data analyses related to safety and 
efficacy), or the accuracy, or the information that 
was written in the manuscript (by the ghostwriters)” 
(p.5); 
(5) “Dr. Evans has been engaged in lending his name to 
ghostwritten articles with the same ‘ghosts’ (i. e., 
Sally Laden) at STI beginning in 1997 to at least 2003” 
(p.6); 
(6) “[Dr. Amsterdam] was intentionally left off from the 
review of the data and the drafting of the manuscript 
because the study sponsor, GSK, and the other 
‘authors’ knew Dr. Amsterdam's professional ethics 
would not allow him to lend his name to a 
ghostwritten work, and most importantly, his morals 
would not allow the alteration and manipulation of 
data and would not allow the other ‘authors’ to turn 
a failed study into an undisclosed promotional 
marketing manuscript for the sponsor” (p.7);  
(7) “despite STI's significant role in the preparation and 
drafting of the manuscript, the final published article 
makes no mention of STI's role in the article and does 
not mention that three of its authors, Ivan P. Gergel, 
M.D., M.B.A., Rosemary Oakes, M.S. and Cornelius 
Pitts, RPh. are GSK employees.” (p. 8); 
(8) “Dr. Nemeroff and Dr. Evans had very little, if any, 
direct input into the daily conduct of the 352 study, 
and certainly not enough to warrant being listed as 
the first and second authors on a manuscript 
published in one of the world's leading medical 
journals. Rather, their positions as authors on the 
manuscript were solely determined by GSK for the 
purpose of appending the names of ‘key opinion 
leaders’ to the manuscript for marketing and 
commercial promotion of paroxetine” (p.10-11). 
 
     In response to these allegations of ghostwriting and 
plagiarism, the University of Pennsylvania and the academic 
authors insisted that there was no involvement with any 
ghostwriters and that the allegations of research 
misconduct were unfounded.14 The academic authors 
insisted that they had personally participated in the drafting 
of the first 352 manuscript. For example, an email press 
release by the University’s spokesperson, Susan Phillips, 
indicated that an inquiry into the misconduct allegations 
“clearly concluded that this was not a case of ghostwriting 
or plagiarism.”14 Likewise, in a public press statement, Dr. 
Evans (who was second author on the published article and 
Chair of the Department of Psychiatry at Penn) wrote: "After 
a thorough review, the inquiry concluded that each and 
every allegation lacked substance and credibility."14 In a 
similar fashion, Dr. Nemeroff (who was first author on the 
published article and Chair of Psychiatry at the University of 
Miami) reportedly told Nature Magazine that, while he was 
aware of STI's involvement in the preparation of the 352 
manuscript, “All Sally Laden did was help collate all the 
different authors' comments and help with references. We 
wrote the paper.”14 In contrast to Nemeroff’s assertion, Dr. 
Gary Sachs (fourth author on the manuscript and Professor 
of Psychiatry at Harvard) told the Boston Globe that he was 
“perplexed” by the allegations of ghostwriting and wrote in 
an email to the reporter: “When the data became available, 
I went to Philadelphia to help Dr. Gyulai [third author on the 
published article and Associate Professor of Psychiatry at 
Penn] draft the manuscript. We started with a blank page.”14 
Sachs also told Science Insider that he did not know that STI 
ghostwriters were involved with the manuscript 
preparation. Finally, Dr. Charles Bowden (fifth author on the 
published manuscript and Professor of Psychiatry at the 
University of Texas Health Science Center) stated: “I never 
had any sense that the manuscript was ‘ghostwritten.’”14  
 
Deconstruction of the Ghostwritten 352 Manuscript 
     On March 13, 1997, the first draft of the 352 
manuscript, prepared by Grace Johnson and Sally Laden of 
STI, was sent to Dr. Muriel Young, Medical Director at GSK. 
The cover page of the manuscript contained no author 
names.15 By early April 1997, GSK senior managers leading 
the project appeared to have made certain alterations to 
the content of the first manuscript draft and these revisions 
were now incorporated into the second manuscript draft. 
An email from Sally Laden to Dr. Young at GSK dated April 4, 
1997, stated:16 
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We are pleased to enclosed Draft II of the manuscript 
“A Double-Blind, Placebo-Controlled Comparison of 
Imipramine and Paroxetine in the Treatment of Bipolar 
Depression.” The manuscript has been modified based on 
your comments and those of Ivan Gergel, Cornelius Pitts, 
and Rosemary Oakes. Please note that some of Dr. 
Gergel's comments in the results section have been 
addressed in the discussion. We have also included one 
set of references as per Dr. Gergel's request. 
Dr. Gergel has confirmed that the American Journal of 
Psychiatry is the target journal for publication. The 
manuscript will be styled according to the journal 
specifications for the submission draft.  
We will contact the named authors (e.g., Laszlo Gyulai, 
Gary Sachs) once we receive your approval. At that time, 
Draft II of the manuscript will be sent immediately to Drs. 
Gyulai and Sachs for their review. 
We look forward to receiving your comments on Draft 
II of the manuscript by April 25, 1997. We will incorporate 
your comments and those of the named authors and 
submit Draft III for your review on May 2, 1997. 
 
This document indicates that the second manuscript draft 
still had no author names listed on its cover page and that 
the manuscript contained only GSK-directed revisions to 
draft #1. The Laden email was only sent to GSK managers for 
their review. This document also indicates that Drs. Gyulai 
(of Penn) and Sachs (of Harvard) were likely designated by 
GSK as the original lead authors on the 352 manuscript. 
Thus, the first two manuscript drafts were entirely 
ghostwritten under the direction of GSK, without any 
contribution from named academic authors. Finally, the 
document suggests that none of the academic authors ever 
saw manuscript draft #1 or #2, until draft #2 revisions were 
completed and verified by GSK.  
     In a subsequent May 1997 correspondence, Cornelius 
Pitts and Ivan Gergel of GSK provided to the STI ghostwriters 
their hand-written revisions to manuscript draft #2. This 
revised manuscript draft indicates that the presentation of 
the post hoc “finding” of positive paroxetine efficacy in 
subjects with low baseline lithium levels was solidified into 
the manuscript text as if it were the primary finding of the 
study. In fact, this was the only “positive” statistical analysis 
for paroxetine in the entire study and, according to the 
study protocol, was unnecessary and should not have been 
performed. This revised draft now contained the omission 
of any weekly mania rating analyses or mania and 
hypomania symptom ratings (which were specifically 
stipulated in the study protocol). Furthermore, without any 
supporting evidence, this revised draft now indicated an 
absence of paroxetine-induced sexual side effects and an 
absence of paroxetine-induced mania. The second draft 
solidified the total sample size of the study at 117 subjects 
as if this were the protocol stipulated sample size. In this 
regard, all information on sample size estimates was 
removed from this draft, and the final power estimate 
provided in this draft was finessed to comport with the 
truncated study enrollment of 117 subjects (rather than the 
projected 186 subjects). Finally, GSK directed the 
ghostwriters to revise the discussion section of the draft to 
lend a favorable commercial spin to paroxetine by having 
them indicate that paroxetine is as efficacious as 
imipramine when, in fact, neither of the medications was 
superior to placebo in any of the outcome analyses.17 Thus, 
for example, while draft #2 reads: “Paroxetine and 
imipramine are comparable in efficacy for the treatment of 
bipolar depression in patients maintained on low-lithium 
levels,” the GSK hand-written revision reads: “Paroxetine 
and imipramine are comparable in efficacy for the 
treatment of bipolar depression showing statistically 
significant superiority to placebo in patients maintained on 
low-lithium levels.”17 STI-edited iterations of these GSK-
directed revisions were all eventually incorporated into the 
published article (p.910).9   
 
Honorary Authorship of Academic Key Opinion Leaders 
     A May 19, 1997 fax from Dr. Young at GSK to Grace 
Johnson at STI provides a revealing picture of how the 
ghostwriters appended the names of the GSK-designated 
“authors” to the developing 352 manuscript. More than 2 
months after the first draft of the manuscript was produced 
for GSK, Dr. Young directed the STI ghostwriter to add the 
following author to draft #3:18 
I would like you to add the following two names as 
authors on the paper: 
 
Charles Nemeroff, M.D. 
Emory Clinic 
1365 Clifton Road, N.E.   
Room 5312, Psychiatry Dept. 
Atlanta, GA 30322 
 
Dwight Evans, M.D. 
University of Florida Health Science Center  
Shands Hospital 1600 S.W. Archer Road 11th Floor  
Gainsville, EL 32610-0486 
 
     Dr. Young then goes on to direct the ghostwriter how 
to arrange the academic authors’ names in the byline of 
draft #3 and which GSK employees to add as authors. She 
wrote:18 
The lead author should be Lazslo Gyulai, then Charles 
Nemeroff, Gary Sachs & Dwight Evans, in that order. The 
other authors are Muriel L. Young, M.D., Ivan P. Gergel, 
Cornelius Pitts, & William Bushnell. Please send a copy of 
the latest draft of the manuscript to Drs. Nemeroff and 
Evans. 
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Thus, this document shows that GSK directed the 
ghostwriters to add Nemeroff and Evans as authors to the 
manuscript after two drafts had already been produced and 
revised by GSK. This GSK-designated order of author names 
would eventually change over time from draft #3 to the final 
manuscript draft. For example, it is noteworthy that, at this 
stage in the manuscript development, there is no mention 
of Dr. Charles Boden as an “author” (although his name will 
appear on later manuscript drafts and on the published 
article). Moreover, with the exception of Drs. Gyulai and 
Sachs (who were initially designated by GSK as lead 
“authors” after draft #2 was completed), the remaining 
academic “authors” only had their names appended to the 
author byline after draft #3 was completed. To this end, on 
May 20, 1997, Grace Johnson of STI confirmed to Dr. Young 
that letters of invitation had indeed been sent to Drs. 
Nemeroff and Evans, inviting them to be listed as “authors” 
on the 352 manuscript. For example, Grace Johnson 
wrote:19 
Dear Dr. Evans: 
By way of introduction, my name is Grace Johnson, and 
I am an editor at Scientific Therapeutics Information, Inc 
(STI). STI is working with Dr. Muriel Young at SmithKline 
Beecham (SB) Pharmaceuticals to develop a manuscript 
"A Double-Blind, Placebo-Controlled Comparison of 
Imipramine and Paroxetine in the Treatment of Bipolar 
Depression." 
We are pleased to invite you to participate as an author 
on this article. Enclosed please find Draft II of the 
manuscript for your review. You may mark your 
comments directly on the manuscript. Please return your 
comments on Draft II of the manuscript by June 12, 1997. 
We will incorporate your comments and those of the 
other reviewers and submit Draft III for your review. 
Following the approval of Draft III, the manuscript will be 
styled for submission to the American Journal of 
Psychiatry. 
Please do not hesitate to contact us with any questions 
or comments during your review. We look forward to 
working with you on this project and to submitting the 
manuscript for publication. 
Thus, despite their later, public assertions that the 352 
article was not ghostwritten, it is clear to us that Dr. Evans 
and Dr. Nemeroff were definitely aware of the existence of 
STI’s involvement in the production of the manuscript. It is 
also clear to us that their names were being appended as 
“honorary” or “guest” authors on the third draft of the 
developing manuscript to which they had made no author 
contributions.  
     A subsequent, internal June 6, 1997 STI memorandum 
from Grace Johnson to her STI associates summarized the 
current status of the 352 manuscript project:20 
D[raft] 2 was sent to SB and Drs. Gyulai and Sachs on 
April 4, 1997. SB added to more authors (Dr. Nemeroff 
and Evans) on May 20, 1997 [sic]. To date, we have 
received comments from Dr, Young, Neil Pitts, and 
William Bushnell. Dr. Gyulai requested SB to complete 
additional statistical analysis on the data. So, D[raft] 2 of 
the manuscript is currently on hold until the analysis is 
complete. The proposal states four drafts. However, with 
so many reviewers and additional statistical analysis on 
D[raft] 2, another draft might be needed. (This may 
depend on if the statistical analysis changes the results 
section of the study.)  
At this point, there were a total of 4 GSK-designated 
academic authors, i.e., Drs. Gyulai, Sachs, Nemeroff, and 
Evans, and 4 GSK employees. Dr. Bowden’s name had not 
yet been added to the author byline. It was also noteworthy 
that Dr. Gyulai’s request for additional post hoc statistical 
analyses by GSK would result in greater production costs to 
the sponsor (see below). Finally, this internal memorandum 
noted that GSK had authorized STI to develop 25 
PowerPoint slides describing the results of the 352 study 
(presumably for marketing and educational purposes). This 
project was to be completed in May 1997, ahead of the 
publication of the 352 article. By December of 1997, it 
appeared that the lead author, Dr. Gyulai, had fallen into 
disfavor with GSK for his requisition of additional statistical 
analyses, which led to a delay in the completion of the 352 
project.   
     In a December 15, 1997 letter from Sally Laden to Dr. 
Nemeroff, Laden indicated that Charles Bowden had now 
been designated by GSK as a 5th academic author and that 
Dr. Gergel of GSK had advised STI that he, Dr. Nemeroff, 
would heretofore be designated by GSK as lead author on 
the 352 project. Laden wrote:21  
Ivan Gergel asked me to send you the enclosed author 
comments on the Paxil bipolar disorder study report. STI 
progressed to the Draft II stage at which point Dr Gyulai 
has held onto the paper without response to us. 
Enclosed are comments from yourself, Dwight Evans, 
and Charles Bowden. 
Ivan mentioned that you will be leading development 
of this manuscript in the future, but that arrangements 
with Dr Gyulai have not yet been finalized. Once I learn 
more from Ivan, I will be in touch with you to discuss our 
next steps. 
Thanks for understanding this process. Please don't 
hesitate to call me if you have questions or require 
additional information. 
 
     Four months after Laden informed Nemeroff that he 
would assume the lead on the 352 project, Laden sent an 
April 3, 1998 proposal to Dr. Gergel at GSK to formalize the 
designation of Nemeroff to restart the stalled 352 project. 
The proposal contained a detailed explanation for an 
additional $10,000 cost of completing the 352 article. It 
further detailed the cost for every step of the ghostwriting, 
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review and submission of the manuscript. The proposal 
stated:22 
STI will develop up to four drafts: Draft I is the initial 
draft that we will receive from Dr Nemeroff and which we 
will edit and follow his direction. This will be reviewed by 
the sponsor and Dr Nemeroff, Comments on Draft I will 
be incorporated into Draft II, which will be sent to the 
same reviewers for review and critique. Draft III is the pre-
journal submission draft and will be sent to the author and 
sponsor for final review and approval prior to developing 
the journal submission package. Draft IV is the journal 
submission draft prepared for the journal, for which art 
work will be professionally drawn and the manuscript 
styled according to the selected journal. 
It should be noted also that page 7 of this April 3rd proposal 
indicates in the “Time and Events” section that SB, i.e., GSK, 
will receive draft 1 from Nemeroff one month after STI 
receives the manuscript. This statement, however, 
contradicts earlier STI documents (cited above). In this 
regard, draft #1 had already been produced by STI on March 
13, 1997.16,17 Thus, irrespective of whether Laden’s April 3, 
1998 designation of “draft #1” is the same as the original 
draft #3, a comparison of the two STI manuscripts makes it 
immediately apparent that both drafts contain the same 
information that is present in the original STI draft #1 from 
March 13, 1997. From our reading of the documents, the 
most plausible interpretation is that the April 3, 1998 STI 
contract from Laden to Gergel did not begin afresh with a 
new 352 draft #1.   
 
Role of the Journal and the Peer-Review Process 
 
     On February 24, 1999, Sally Laden (under Dr. 
Nemeroff’s name) began the submission process of the 352 
manuscript to the American Journal of Psychiatry.  Laden 
wrote to each GSK-designated author to obtain their signed 
copyright release to the journal. The “Manuscript 
Submission Approval and Copyright Transfer” reads:23 
I have been sufficiently involved in this work to take 
public responsibility for its validity and final presentation 
as an original publication. I can and will provide 
documentation of my work upon reasonable request and 
I have fulfilled the obligations for full disclosure and 
authorship as described by the American Journal of 
Psychiatry. 
In a subsequent communication from Laden to Nemeroff 
dated March 5, 1999, Laden informed Nemeroff that: 24 
After I sent what I thought was the final version (SB had 
given it their blessing) to all authors for their sign-off, Dr 
Gyulai pointed out that the ad-hoc analysis of high vs low 
HAMD patients excluded those patients with thyroid 
changes. SB quickly re-ran the data and found that the 
significant differences between imipramine and placebo 
and the trends for paroxetine were lost. Thus, we deleted 
Figure 2 and deleted one sentence from the text. Because 
this wasn't the main point of the paper, I'm hoping that 
this change is OK. I’m assuming that it is and am sending 
the submission package to you today. 
Thus, it appears that Laden unilaterally revised the 
manuscript (i.e., without any consultation from the 
academic or GSK authors) to avoid reporting the newly-
analyzed, post hoc “negative” finding. Thus, if Laden had not 
made this unilateral editorial decision, there may have been 
no “positive” analyses of any sort to report on paroxetine. 
An email thread between Nemeroff and Laden dated 
July 13, 1999 that was forwarded to Cornelius Pitts at GSK 
provided information on the peer-review status of the 352 
manuscript by the American Journal of Psychiatry. Laden 
wrote: 25 
I'm reviewing my list of projects with SB and have a few 
questions. 1. Have you heard from Am J Psychiatry about 
the bipolar paper?... 
Nemeroff responds:25 
I am in Zurich as I respond at midnight visiting with 
Roche.  The answers are: 1. Jack Gorman [Deputy Editor 
of the American Journal of Psychiatry] told me that the 
Bipolar paper has come back from review and will be 
accepted after revisions. I haven't received the reviews 
yet but you will be the first to know, I promise.…We love 
working with you. 
A subsequent September 13, 1999 email from Laden to 
Nemeroff (copied to Pitts at GSK) provided additional 
information on the status of the peer-review process. 
Apparently, the peer-reviewed manuscript was returned 
from the American Journal of Psychiatry and was back on 
the desk of Sally Laden at STI. Laden informed Nemeroff that 
extensive revisions were requested by the reviewers and 
that many of the comments involved statistical issues that 
she could not address, as she (i.e., Laden) revised the peer-
reviewed manuscript. As a result, Laden sent the partly-
revised manuscript to Pitts at GSK to address the requested 
statistical revisions with the GSK statistician. Laden wrote to 
Nemeroff: 26 
Last week, I finished with my first cut at the Am J Psych 
reviewers’ extensive comments to this paper. Many of 
their comments were statistical in nature, which only the 
SB statistician can answer. Neil Pitts has it now and I’ll stay 
in touch with him about the progress of their review. 
A subsequent email exchange, between Laden and Pitts, 
dated March 15, 2000 provides more insight into the 
STI/GSK revisions that were made to the 352 manuscript. 
The revisions suggested by Pitts to Laden were 
memorialized in an email “note-to-file” made by Sally Laden 
to herself: 27 
Note to self: 
make these changes to the bipolar manuscript 
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1. emphasize that only 5 of 8 patients were in the 
efficacy population and this didn’t come through in the 
manuscript revision. 
2. tone it down and the efficacy of those 5 patients who 
had efficacy change scores was similar to the overall 
study. 
In a subsequent April 5, 2000 email, Laden provides 
Nemeroff with a further update on the revisions of the 352 
manuscript: 28 
The bipolar manuscript has been revised [by GSK] to 
include the statistical reanalysis, and Rocco Zanninelli and 
Neil Pitts have signed off on it. It is being fedexed to you 
tomorrow and you will receive it on Wednesday. If you 
approve the manuscript, I will prepare a brief response to 
the journal so that you can resubmit it.… Again, upon your 
approval to proceed, I'll have a submission package 
prepared for you to submit the manuscripts to the 
journal. 
This email from Laden to Nemeroff, together with the 
September 13th email exchange above, indicate to us that 
Nemeroff and the other academic authors had little or no 
scientific input into the original or revised 352 data analyses 
and that virtually all of the revisions were made by Sally 
Laden and GSK employees i.e., Drs. Zaninelli, Pitts, Oakes, 
and Gergel. Sally Laden, and not Nemeroff, wrote the 
revision cover letter to the editor of the American Journal of 
Psychiatry) (i.e., Jack Gorman). In a somewhat curious 
addendum to this email exchange, Nemeroff wrote to 
Laden: 28 
Ivan Gergel, MD who was with SKB and was a coauthor 
[on manuscript draft #3] must be reinserted as a 
coauthor. I will not compromise on this as he was involved 
in the early drafts and this is simply an ethical issue. 
Dwight and other authors agree about this. We must take 
the high road here.  
 
     In an email dated May 11, 2000, Laden wrote to Dr. 
Evans and the other academic authors indicating that she 
needed their approval of the revised 352 manuscript that 
was prepared for Nemeroff. Laden advised the authors of 
the revision process:29 
Significant re-analysis has been accomplished and the 
revisions have been made and approved by Dr Nemeroff, 
Rocco Zaninelli, MD (of SB), and Neil Pitts, RPh (of SB). Dr 
Nemeroff will be submitting the revised manuscript to the 
journal early next week.  A copy of the revised manuscript 
(note that new references are not yet renumbered) and 
Dr Nemeroff s point-by-point rebuttal to the journal are 
attached in WORD files below.   
Evans responded to Laden:29 
Dear Sally, 
Masterful! No additional changes recommended. 
Dwight  
An email dated June 12, 2000, indicated that further 
difficulties had arisen in publishing the 352 manuscript. It 
appears that the American Journal of Psychiatry had sent 
the revised manuscript to an additional, independent 
statistical reviewer who rejected the revised manuscript and 
instead recommended additional analyses, revisions and 
the elimination of all commercial bias. Although the official 
letter from Gorman to Nemeroff, printed on American 
Journal of Psychiatry letterhead, was not sent to Nemeroff 
until June 22, 2000, concerns about the manuscript were 
already being expressed by the STI ghostwriter and GSK. In 
this regard, Laden wrote to Nemeroff on June 12th: 30 
Thanks for copying me on the email from Jack 
[Gorman] about Am J Psychiatry's review. I've passed this 
along to SB and await their reaction. What are your 
feelings about this? 
Nemeroff responded to Laden:30 
Jack is clearly willing to fight for the paper. The 
statistician's point is well taken, namely the secondary 
hypothesis testing. I think we should see if the SB 
statisticians are able to respond adequately to the 
criticisms and moreover if we can tone down the 
perceived commercial bias so Jack can pull it over the line.  
If not, we can publish it relatively quickly in Depression 
and Anxiety. I can use the AJP reviews from the first 
review. 
Laden replied to Nemeroff that she will pass the information 
about the need for additional revisions and the assistance 
from Jack Gorman to the GSK managers. Gorman had 
significant financial ties to GSK as a recognized key opinion 
leader, member of GSK’s psychiatry advisory board, 
speakers’ bureau and frequent spokesperson for paroxetine 
(Paxil) on television programs and advertisements.31 
    Despite Nemeroff’s reassurance to Laden, it appears 
that GSK was, nonetheless, increasingly frustrated with the 
additional time, cost, and uncertainty of getting the 352 
manuscript published in the American Journal of Psychiatry. 
To wit, an internal email among STI employees, dated June 
13, 2000, revealed GSK’s dissatisfaction with STI’s ghost 
management of the 352 project. Marion Philips and Sally 
Laden describe to STI President (John Romankiewicz) the 
extent of GSK’s dissatisfaction:32 
Marion - this project (the bipolar paroxetine 
manuscript) has come into trouble with the client [i.e., 
GSK]. It has been a protracted process - we are currently 
at Draft XI, if my calculations are correct. They are 
disgusted with the author (Charlie Nemeroff) and with the 
fact that they have to pay an agency [i.e., STI] extra to get 
it done. Remember, this is the client (Rocco Zaninelli 
[Medical Director at GSK] who refuses to work with any 
outside medical writers, including STI. A brief history is 
this:  
1. Submitted to Am J Psychiatry, 
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2. Journal sent back significant revisions, but no 
promise of acceptance 
3. Many drafts later, the revised version (draft X or XI) 
was resubmitted 
4. Yesterday, journal responded that they might 
consider it, but significant revision was still needed. 
5. Charlie Nemeroff feels that with more revision we 
might get it in the Am-J Psychiatry, but that we could 
probably get it published in his journal (Depression & 
Anxiety or the British J Psychiatry) 
I advised client of this immediately. They responded by 
saying that they don’t care where it is published, they just 
don’t want to be charged extra. They want to turn this 
[i.e., the production of the 352 manuscript] over to 
Charlie so that he can finish it up. 
 
     Meanwhile, behind the scenes, a private email from 
Gorman to Nemeroff, dated June 12, 2000, detailed how 
Gorman could facilitate the revision and publication of the 
rejected 352 manuscript. Gorman indicates that he was not 
quick enough in forestalling the statistical reviewer from 
rejecting the 352 manuscript; but would nonetheless get it 
published, with GSK’s direct assistance. Gorman wrote:33 
I got the bipolar depression paper back and wanted to 
give you a heads up. The revision went automatically to 
the statistical reviewer before coming to me, which is the 
usual custom on resubmitted manuscripts. The statistical 
reviewer adamantly recommends rejection. I read it again 
carefully and I still think the paper is important as one of 
the only if not the only one of its kind. However, journals 
are now under fierce scrutiny about drug company 
sponsored studies, thanks in large part to Marcia Angel’s 
recent stuff in the NEJM.  
The paper still has a very biased tinge to it. Look, the 
fact is that the study was beautifully designed and the 
results are important. But in the high lithium level group 
the two active drugs did no better than placebo and it is a 
legitimate conclusion that raising the lithium level alone 
may be sufficient to treat bipolar depression. I think you 
would want to make that point much more strongly. 
Second, using the main analyses, the ITT for all groups, 
there is no statistically significant drug versus placebo 
effect. The journal will never allow ‘numerical superiority’ 
as a standard. So the second conclusion is that for the 
study as a whole, drugs didn't do better than placebo. 
In a secondary analysis you can show that if you don't 
want to raise lithium level, there is a completer finding 
that imipramine and paroxetine are better than placebo, 
but it must be labelled as a very post hoc observation. 
Finally, we all know that paroxetine is better tolerated 
than imipramine but I don't see it in this data set. None of 
the comparisons for adverse side effects or drop outs is 
statistically significant, [and] the claim that paroxetine is 
better on that basis than imipramine is not warranted. 
You’ll get all this back in the form of an invitation to 
revise again. Even if I bend, no way NCA [Nancy C. 
Andreason, Chief Editor] would allow it in its present state 
so it is moot for me to go ahead. I think you might want to 
go over it again with the SKB people and let them know 
that the study just doesn't support much in the way of a 
claim that paroxetine worked particularly well here 
compared to other interventions. 
If I’ve missed something, of course let me know. I want 
to be helpful and this was a lot of work and a great study. 
 
     In follow up to this June 12th, back channel email from 
Gorman to Nemeroff, Laden sent a fax correspondence on 
July 5, 2000 to Drs. Raj Kumar and Rocco Zaninelli of GSK to 
reassure them that the 352 manuscript would most 
probably be accepted for publication by the journal editor, 
if a few minor cosmetic revisions were made to the 
manuscript. However, Laden also recognized that GSK may 
not want to expend additional time and money on 
publishing the 352 manuscript in the American Journal of 
Psychiatry; in which case it will definitely be accepted in 
Nemeroff’s Depression & Anxiety journal.34 
     It appears that Nemeroff was probably successful in 
gaining Dr. Kumar’s approval to have GSK continue working 
with STI and Gorman. As a result, Dr. Kumar agreed to allow 
STI to move forward with another revision. This resulted in 
a July 26, 2000 letter in which Laden writes to Kumar:35 
At the request of Charlie Nemeroff, I am enclosing the 
most recent correspondence from Am J Psychiatry related 
to this manuscript. Charlie tells me that you are willing to 
continue revising this manuscript and submit it a third 
time to the journal. According to Charlie, this will be 
accomplished as follows: 
 1. Rosemary Oakes will address the statistical 
reviewer's comments and make changes to the 
manuscript. 
 2. When done, she will send these changes to STI to 
be incorporated into the manuscript. 
 3. STI will send the revised manuscript to Charlie, 
who will revamp it and remove the 'marketing' tone to 
which the journal objected. 
 4. Charlie will either submit the manuscript directly 
or return it to STI to be restyled for resubmission to the 
journal. 
Enclosed please find a copy of the manuscript plus the 
journal's reviews and correspondence. 
I trust that this is an accurate summary of the 
agreement made to finish this project. If not, kindly 
contact me directly.  
 
     A subsequent October 31, 2000 email from Laden to 
Nemeroff details the revisions that were made by Laden and 
GSK to the 352 manuscript. Laden indicates that the revised 
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manuscript fulfills all of Gorman’s June 22, 2000 officially-
recommended revisions. Laden wrote to Nemeroff:36 
The changes consist of the addition of more statistical 
detail in Table 2 and greatly toned down [the commercial] 
text in the Abstract, Results, and Discussion about the 
findings. 
Laden notes that:36 
… this version is sufficiently noncommercial and fulfills 
the directives outlined by the journal. 
Finally, Laden indicates to Nemeroff that if he approves the 
Gorman and GSK-recommended revisions, she will prepare 
a submission packet for Nemeroff containing:36 
 a detailed response to the reviewers, 4 copies of the 
manuscript and cover letter, a new glossy for the figure, 
and all files on a disk. 
 
     On November 11, 2000, Laden ghostwrote a cover 
letter (in Nemeroff’s name) to Jack Gorman at the American 
Journal of Psychiatry, detailing the second revision to the 
352 manuscript.37 This letter was then placed on Emory 
letterhead for submission to the journal via Nemeroff’s 
office staff. The cover letter states that the report of the 352 
trial:37 
represents the largest placebo-controlled trial of 
bipolar depression ever conducted [sic], and contains 
important and novel information to the field.  
It is noteworthy, however, that there is no mention of the 
study being prematurely terminated for insufficient subject 
enrollment or that it had insufficient power to test any of 
the primary or secondary study aims. It also states that the 
study outcomes are unique, when, in fact, the GSK authors, 
journal reviewers and journal editor noted that the study 
was a negative trial.24,33 
     While the peer-review and revision process of the 352 
manuscript finally resulted in its acceptance for publication 
by the American Journal of Psychiatry on January 6, 2001, 
we would note that this process (such as it was) failed to 
adhere to the International Committee of Medical Journal 
Editors (ICMJE) policy regarding authorship, according to 
which both honorary authorship and ghost authorship are 
considered forms of misconduct. The American Journal of 
Psychiatry policy in place at the time of the submission of 
the Nemeroff et al. manuscript stated:38 
All persons designated as authors should qualify for 
authorship. Each author should have participated 
sufficiently in the work to take public responsibility for the 
content.  
Authorship credit should be based on substantial 
contributions to: 1) conception and design or analysis and 
interpretation of data, and 2) drafting the article or 
revising it critically for important intellectual content, and 
on 3) final approval of the version to be published. 
Conditions 1, 2, and 3 must all be met. Participation solely 
in the acquisition of funding or the collection of data does 
not justify authorship. General supervision of the research 
group is also not sufficient. Any part of an article critical 
to its main conclusions must be the responsibility of at 
least one author. 
Only those with key responsibility for the material in 
the article should be listed as authors; others contributing 
to the work should be recognized in an 
Acknowledgement. Editors will require authors to justify 
the assignment of authorship. 
 
On September 22, 2016, the current authors wrote to 
the American Journal of Psychiatry Chief editor, Robert 
Freedman, to request retraction of the Nemeroff et al. 
article on the basis of the violation of journal policy and the 
misrepresentation of study 352 results. Dr. Freedman did 
not respond, and thus the scientific record remains 
uncorrected. (The letter from the current authors is 
published as a supplemental file to this article). 
      
Discussion 
     The paroxetine 352 study was a non-informative trial 
with insufficient statistical power to show anything but 
inconclusive results. There was no evidence of any 
paroxetine (or imipramine) efficacy relative to placebo in 
bipolar major depression and the suppression of safety data 
hid the presence of paroxetine-induced harm.  
     The misrepresentation of the 352 study as a published 
report was facilitated by STI ghostwriters working in 
conjunction with GSK employees and the editor of the 
American Journal of Psychiatry. Given the documentary 
evidence presented above, and despite their uniform 
denials to the Penn ORI Inquiry Committee, it is difficult to 
see how the academic authors could not have been aware 
that a medical writing firm was involved in the manuscript 
production. Moreover, most of the academic authors 
apparently misled the American Journal of Psychiatry by 
appending their signature to the “Manuscript Submission 
Approval and Copyright Transfer” that claimed they were 
sufficiently involved in the work to take public responsibility 
for its validity and final presentation. These academic 
“authors” failed to adhere to the journal’s authorship 
criteria and they violated the policy by failing to disclose the 
role of STI and GSK in the development of multiple 
manuscript drafts.   
     The only mention in the published Nemeroff et al. 
article of drug company support is the rather misleading 
statement, “Supported by NIMH grant MH-51761 and a 
grant from GlaxoSmith-Kline,” suggesting that the primary 
financial support for the 352 study was provided by a NIMH 
supported grant with secondary support from GSK.9 This, of 
course, was not the case.   
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      From our deconstruction of the documentary 
evidence, it appears that none of the academic authors had 
access to, or reviewed, the actual patient-level data or the 
repeated GSK-produced data analyses and it is certainly 
false that they had complete freedom to direct its analysis 
and its reporting without influence from the sponsor. We 
would also note that the ethical protestation by Nemeroff, 
Evans and the other academic authors regarding the guest 
authorship of Ivan Gergel [after his departure from GSK to 
Forest Laboratories, Inc.] is ironic given the fact that none of 
the academic “authors” had any involvement in the 352 
study and that they were all designated by GSK for inclusion 
in the author byline. It is also obvious to us that the journal 
editor, Jack Gorman, took unethical and unprofessional 
editorial license with the journal peer-review process in 
order to facilitate publication of the 352 manuscript. 
Gorman also failed to have the 352 authors justify the 
assignment of authorship. In our view, the authorship policy 
of the American Journal of Psychiatry is largely window 
dressing common for journals of the sort that publish 
industry-sponsored trials.  
     The ORI Inquiry Committee of the University of 
Pennsylvania ignored the allegations of research 
misconduct in the performance of the 352 study and, 
instead, focused on the ghostwriting aspect of the published 
article. In this regard, Penn failed to examine the available 
evidence in the case and ignored the most egregious 
evidence of misconduct, i.e., the newly-posted STI 
documents. This omission allowed the University to avoid 
public embarrassment and to clear their professors of any 
wrongdoing. Thus, instead of punishing their professors for 
academic misconduct, the University whitewashed the 
presence of any misconduct within its psychiatry faculty. 
Penn’s conclusion of no wrongdoing by its professors 
provoked such a public outcry of indignation that the issue 
of ghostwriting at the University of Pennsylvania reached 
the desk of the President of the United States.39 
 
Conclusion 
     Because ghostwriting is designed to evade detection 
and is only revealed as a result of litigation or government 
inquiries, it is therefore imperative to document the cases 
in which ghostwriting has facilitated misrepresentation of 
clinical trial results. The integrity of science depends on the 
trust placed in individual clinicians and researchers and in 
the peer-review system which is the foundation of a reliable 
body of knowledge.  When academic researchers allow their 
names to appear on ghostwritten articles, they betray this 
basic ethical responsibility and are guilty of academic 
dishonesty. Medical journal editors are entrusted with 
significant power as gatekeepers of the scientific record. 
They also bear the responsibility to ensure that the journals 
are not publishing manuscripts guilty of fraud, fabrication 
and plagiarism. Ghostwriting is a serious problem because it 
is a dishonest attribution of the origin of the manuscript, it 
disguises marketing and public relations objectives of for-
profit companies as science, conceals conflicts of interest of 
named “authors” on manuscripts, misrepresents the results 
of scientific testing, and, most importantly, has contributed 
to fatal consequences in cases in which the safety of drugs 
are misreported. 
 
Limitations 
     The authors warrant that findings have been reported 
fairly and non-selectively. It is, however, always possible 
that there are gaps in the record due to inadequate 
response to discovery in litigation. Since the complete 
deconstruction of each STI document could not be 
exhaustively undertaken in the course of this review, we  
recommend that readers  examine each STI document that 
is posted on the Drug Industry Document Archive (DIDA) 
web-site at the University of California San Francisco (see 
https://www.industrydocuments.ucsf.edu/drug/collections
/paxil-litigation-documents/). 
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